At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Perfusion CT as Predictive Biomarker in a Phase II Study of Ziv-Aflibercept in Patients With Advanced Pancreatic Neuroendocrine Tumors
In Brief
A Phase 2 clinical trial evaluating Computed Tomography Perfusion Imaging, Laboratory Biomarker Analysis, and 1 other intervention for Multiple Endocrine Neoplasia Type 1 and Pancreatic Neuroendocrine Carcinoma. Completed, enrolled 22 participants across 3 sites.
Detailed Summary
This phase II trial studies ziv-aflibercept in treating and perfusion computed tomography perfusion imaging in predicting response in patients with pancreatic neuroendocrine tumors that have spread to other parts of the body or cannot be removed by surgery. Ziv-aflibercept may stop the growth of tumor cells by blocking blood flow to the tumor. Diagnostic procedures, such as computed tomography perfusion, imaging may help measure a patient's response to ziv-aflibercept treatment.
Study Details
Timeline
Interventions
Undergo computed tomography perfusion imaging
Correlative studies
Given IV